William Chey and colleagues performed a meta-analysis and systematic review of five randomized, placebo-controlled trials to determine the efficacy and tolerability of the minimally absorbed antibiotic rifaximin in patients with IBS. Rifaximin was more effective than placebo for global IBS symptom improvement and bloating. Adverse effects were similar among patients in the two groups.